subslover
4 months ago
Meihua International Medical Technologies Facilitates World's Second* 5G Remote Robot-Assisted Lobectomy
YANGZHOU, China, July 31, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today announced that its NT-2000 surgical path analysis system successfully supported the world's second* 5G remote robot-assisted lobectomy. This procedure, we believe the first of its kind in China's Yangzi Delta area, was performed on July 15, 2024, at Yangzhou University Affiliated Hospital by a team from Shanghai Chest Hospital.
"We are honored that our cutting-edge technology could assist the advanced 3D imaging for surgical mapping in this sophisticated procedure," said Mr. Yongjun Liu, Chairman of Meihua, "Despite a physical distance of over 200 kilometers between the surgical team and the patient, the operation was executed seamlessly in just one hour, thanks to 5G technology and the precision of the robotic surgical system. We believe that robot-assisted surgery has made significant strides due to its clinical effectiveness, low risk, and quick recovery times. We also believe that successful implementations improve the quality of medical services, allowing patients to access diverse, personalized, and high-quality healthcare locally. We anticipate that this innovation will not only ease the workload on medical staff but also address disparities in medical resource distribution across China. Moving forward, Meihua will continue in its efforts to innovate and enhance healthcare outcomes for patients."
The development of Meihua's robotic surgical systems is part of the Company's strategic initiatives to increase sales of high-end products and broaden its customer base. The Company has introduced new overseas technologies, including minimally invasive surgical robot systems, and established a dedicated research and development team focused on robotic-assisted surgery (RAS) systems. The Company believes its NT-2000 system's real-time monitoring and guidance capabilities enable precise targeting of surgical sites, improving the accuracy and success rates of operations. The RAS project is being developed in conjunction with the Hope City Medical Park in Hainan province, China. The project is expected to be completed in the fall of 2025.
* We believe this is the World's second 5G remote robot-assisted lobectomy, as reported by Yangzhou University Affiliated Hospital: https://mp.weixin.qq.com/s/HuApwLs3V8rRib1nSpUMXQ and Yangzhou Daily: http://news.yznews.com.cn/2024-07/27/content_7674119.htm.
81vette
9 months ago
well said bro,yea trading has changed more in last 2 years than in all the 30 i have traded,darkpool mm blackrock crooks with ai algos can steal about 90% of moves between bid and ask,(10% used to be acceptable) it has forced trading to evolve to selling even the most promising ticker if its not running up 150% every 5min(slight exaggeration) or if it pulls back 30% from 150%(its still up 120%,but to many ppl bought around same pps because of mms theft) ,causing more of what ppl call pump and dumps,implying/thinking its the ticker co. fault,(very few are), i dont blame traders,protecting profit/preventing loss is essential to survival, our forced new way to trade is moving more wealth from middle class to big banks(the mms) than ever before
PennyPusher786
10 months ago
What I don't understand is this... is this a dilutive offering?
Meihua International Medical Technologies Co., Ltd. Announces Closing of Initial $6 Million Tranche of Potential $50.5 Million Maximum Offering
Source: PR Newswire (US)
YANGZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today announced the closing of its previously disclosed registered direct offering with certain accredited institutional investors to purchase an initial $6 million tranche in the offering of up to $50.5 million of its 7% Original Issue Discount Senior Convertible Promissory Notes (the "Initial Notes"), and five-year ordinary share purchase warrants to purchase 1,205,255 ordinary shares of the Company (the "Initial Warrants"), exercisable at $2.9869 per ordinary share, in a concurrent private placement, for gross proceeds of approximately $5,580,000.